Literature DB >> 24025779

Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction.

Thierry Perez1, Pascal Chanez, Daniel Dusser, Philippe Devillier.   

Abstract

Asthma is a disease characterized by inflammation which affects both proximal and distal airways. We evaluated the prevalence of small airway obstruction (SAO) in a group of clinically stable asthmatics with both normal forced expiratory volume in the first second (FEV1) and normal FEV1/forced vital capacity (FVC) and treated with an association of inhaled corticosteroids (ICSs) and long acting β2-agonists (LABAs). Clinical evaluation included the measurement of dyspnea, asthma control test and drug compliance. The prevalence of SAO was estimated by spirometry and plethysmography and defined by the presence of one or more of the following criteria: functional residual capacity (FRC) > 120% predicted (pred), residual volume (RV) > pred + 1.64 residual standard deviation (RSD), RV/total lung capacity (TLC) > pred + 1.64 RSD, forced expiratory flow (FEF)25-75% < pred - 1.64 RSD, FEF50% < pred - 1.64 RSD, slow vital capacity (SVC) - FVC > 10%. Among the 441 patients who were included, 222 had normal FEV1 and FEV1/FVC. At least one criteria of SAO was found in 115 (52%) mainly lung hyperinflation (39% based on high FRC, RV or RV/TLC) and more rarely distal airflow limitation (15% based on FEF25-75% or FEF50%) or expiratory trapping (10% based on increased SVC - FVC). In the patients with only SAO (no PAO), there was no relationship between SAO, asthma history and the scores of dyspnea, asthma control or drug compliance. These results suggest that in asthmatics with normal FEV1 and FEV1/FVC, treated with ICSs and LABAs, SAO is found in more than half of the patients indicating that the routinely used lung function tests can underestimate dysfunctions occurring in the small airways.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; Hyperinflation; Small airways

Mesh:

Substances:

Year:  2013        PMID: 24025779     DOI: 10.1016/j.rmed.2013.08.009

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  21 in total

1.  [Comparison of functional parameters of small airways between patients with typical asthma and cough-variant asthma].

Authors:  Shu-Yu Chen; Ze-Kui Fang; Si Fang; Qi-Xiao Shen; Xi He; Cui-Lan Wang; Hua-Peng Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

2.  Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.

Authors:  Guang-Shing Cheng; Barry Storer; Jason W Chien; Madan Jagasia; Jesse J Hubbard; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Kristina Crothers; Iskra Pusic; Stephanie J Lee; Kirsten M Williams
Journal:  Ann Am Thorac Soc       Date:  2016-11

3.  Use of FEF25-75% to Guide IgG Dosing to Protect Pulmonary Function in CVID.

Authors:  Tracy Hwangpo; Zhixin Wang; Jack Ghably; Surya P Bhatt; Xiangqin Cui; Harry W Schroeder
Journal:  J Clin Immunol       Date:  2020-01-03       Impact factor: 8.317

4.  Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma.

Authors:  Craig M Riley; Sally E Wenzel; Mario Castro; Serpil C Erzurum; Kian Fan Chung; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Wendy C Moore; Eugene R Bleecker; William J Calhoun; Nizar N Jarjour; William W Busse; Stephen P Peters; W Gerald Teague; Ronald Sorkness; Fernando Holguin
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN).

Authors:  F Braido; N Scichilone; F Lavorini; O S Usmani; L Dubuske; L P Boulet; R Mosges; C Nunes; M Sanchez-Borges; I J Ansotegui; M Ebisawa; F Levi-Schaffer; L J Rosenwasser; J Bousquet; T Zuberbier; G Walter Canonica; A Cruz; A Yanez; A Yorgancioglu; D Deleanu; G Rodrigo; J Berstein; K Ohta; P Vichyanond; R Pawankar; S N Gonzalez-Diaz; S Nakajima; T Slavyanskaya; A Fink-Wagner; C Baez Loyola; D Ryan; G Passalacqua; J Celedon; J C Ivancevich; K Dobashi; M Zernotti; M Akdis; S Benjaponpitak; S Bonini; W Burks; L Caraballo; Z Awad El-Sayed; S Fineman; P Greenberger; E Hossny; J A Ortega-Martell; H Saito; M Tang; L Zhang
Journal:  World Allergy Organ J       Date:  2016-10-28       Impact factor: 4.084

Review 6.  Small airways dysfunction in asthma: evaluation and management to improve asthma control.

Authors:  Omar S Usmani
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-18       Impact factor: 5.764

Review 7.  Techniques of assessing small airways dysfunction.

Authors:  William McNulty; Omar S Usmani
Journal:  Eur Clin Respir J       Date:  2014-10-17

8.  Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN).

Authors:  F Braido; N Scichilone; F Lavorini; O S Usmani; L Dubuske; L P Boulet; R Mosges; C Nunes; M Sánchez-Borges; I J Ansotegui; M Ebisawa; F Levi-Schaffer; L J Rosenwasser; J Bousquet; T Zuberbier; G Walter Canonica
Journal:  Asthma Res Pract       Date:  2016-10-28

Review 9.  Small airway dysfunction and bronchial asthma control : the state of the art.

Authors:  Marcello Cottini; Carlo Lombardi; Claudio Micheletto
Journal:  Asthma Res Pract       Date:  2015-12-01

10.  Bronchial thermoplasty reduces gas trapping in severe asthma.

Authors:  David Langton; Alvin Ing; Kim Bennetts; Wei Wang; Claude Farah; Matthew Peters; Virginia Plummer; Francis Thien
Journal:  BMC Pulm Med       Date:  2018-09-24       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.